NEW YORK, June 18, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of  Petco Health and Wellness Company, Inc. (“Petco” or the “Company”) (NASDAQ: WOOF).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Petco and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.  [Click here for information about joining the class act ...

BENSALEM, Pa., June 17, 2025 (GLOBE NEWSWIRE) -- Law Offices of Howard G. Smith continues its investigation on behalf of Neogen Corporation (“Neogen” or the “Company”) (NASDAQ: NEOG) investors concerning the Company’s possible violations of federal securities laws. IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN NEOGEN CORPORATION (NEOG), CONTACT THE LAW OFFICES OF HOWARD G. SMITH ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS. Contact the Law Offices of Howard G. Smith to discuss your legal rights by ...

the main focus for those who are at the crash scene in India. Seeing if there are any survivors at all. There have been reports that there are obviously many fatalities.Whether or not anybody was able to survive this crash, we don't know at this point. In terms of the investigation into the accident, that's going to take some time. The first uh priority is looking for survivors and then after that those victims who were killed in the crash, removing those bodies, then investigators will be able to say, "Oka ...

NEW YORK, June 09, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against SoundHound AI, Inc. (NASDAQ:SOUN) on behalf of long-term stockholders following a class action complaint that was filed against SoundHound on March 28, 2025 with a Class Period from May 10, 2024 and March 3, 2025. Our investigation concerns whether the board of directors of SoundHound have breached their fiduciary duties to the company. Accor ...

SAN DIEGO, June 06, 2025 (GLOBE NEWSWIRE) -- The law firm of Robbins Geller Rudman & Dowd LLP is investigating potential violations of U.S. federal securities laws involving EchoStar Corporation (NASDAQ: SATS) focused on whether EchoStar and certain of its executives made false and/or misleading statements and/or failed to disclose material information to investors. If you have information that could assist in the EchoStar investigation or if you are an EchoStar investor who suffered a loss and would like t ...

Core Viewpoint - Cellebrite has announced its agreement to acquire Corellium for an enterprise value of $170 million in cash, enhancing its capabilities in digital investigations and security for smart devices [2][3] Company Overview - Cellebrite is a global leader in digital investigative solutions, focusing on enhancing digital investigations and intelligence gathering to accelerate justice [6] - Corellium specializes in Arm hypervisor virtualization, providing solutions for security and developer teams to build, test, and secure software for mobile, automotive, and IoT devices [7] Acquisition Details - The acquisition is valued at $170 million, with $20 million converted to equity at closing, and an additional $30 million contingent on performance milestones over the next two years [2] - The deal is expected to close in summer 2025, pending approval from the Committee on Foreign Investment in the United States [2] Strategic Benefits - The combination of Cellebrite and Corellium is expected to set a new standard for digital investigations and enhance the security of Arm-based devices across various applications [1] - Corellium's technology will broaden Cellebrite's Total Addressable Market (TAM) in both public and private sectors, enhancing its Digital Investigation Platform and mobile vulnerability research capabilities [1][2] Technological Advancements - The acquisition will enable accelerated identification of mobile vulnerabilities and exploits, and provide an industry-first ability to visualize and interact with virtual devices [4] - Corellium's virtualization platform will enhance DevSecOps efficiency across all Arm-based devices, facilitating the development of high-performance, secure mobile applications and IoT devices [4][1]

Core Viewpoint - Ichor Holdings, Ltd. is under investigation for potential violations of federal securities laws and unlawful business practices following disappointing financial results in Q1 2025, which led to a significant drop in stock price [1][2]. Financial Performance - On May 5, 2025, Ichor reported its Q1 2025 financial results, missing both EPS and revenue consensus estimates [2]. - The company reported a gross margin of 12.4%, which is below the forecasted midpoint of 14.5% [2]. - Ichor attributed the margin shortfall to purchasing more external supply than anticipated, which did not translate into expected margin flow [2]. Legal Investigation - Bragar Eagel & Squire, P.C. is investigating potential claims against Ichor on behalf of stockholders who may have suffered losses [1][3]. - The investigation focuses on whether Ichor has engaged in unlawful business practices or violated federal securities laws [1].

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices by Rocket Pharmaceuticals and its officers or directors following a serious adverse event in a clinical trial that led to a significant drop in the company's stock price [1][3]. Group 1: Company Developments - On May 27, 2025, Rocket Pharmaceuticals announced an unexpected serious adverse event (SAE) related to its investigational gene therapy RP-A501 for Danon disease, which involved clinical complications from capillary leak syndrome [3]. - Following the SAE, Rocket voluntarily paused further dosing in the Phase 2 pivotal trial, and the FDA placed a clinical hold on the trial for further evaluation [3]. - The patient involved in the SAE subsequently passed away due to an acute systemic infection [3]. Group 2: Market Reaction - The announcement of the SAE resulted in Rocket's stock price falling by $3.94 per share, a decrease of 62.84%, closing at $2.33 per share on May 27, 2025 [3]. Group 3: Legal Context - Pomerantz LLP, a prominent firm in corporate and securities class litigation, is representing investors in the investigation regarding Rocket Pharmaceuticals [1][4].

BOSTON, May 27, 2025 (GLOBE NEWSWIRE) -- Block & Leviton is investigating Savara Inc. (Nasdaq: SVRA) for potential securities law violations. Investors who have lost money in their Savara Inc. investment should contact the firm to learn more about how they might recover those losses. For more details, visit https://blockleviton.com/cases/svra. What is this all about? Shares of Savara fell over 30% in intraday trading on May 27, 2025, after the company announced that the FDA issued a Refusal to File letter f ...

UnitedHealth shares fell more than 4% on Wednesday after the UK’s Guardian newspaper reported that the company made secret payments to nursing homes to reduce hospital transfers, adding to the woes of the healthcare conglomerate.The alleged action, part of a series of cost-cutting tactics, has saved the company millions, but at times risked residents’ health, the Guardian reported, citing an investigation.The allegations add to the litany of negatives that have hurt UnitedHealth in the last several months, ...